This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

VirtualScopics, Inc. Schedules First Quarter 2014 Financial Results Press Release And Conference Call

ROCHESTER, N.Y., May 1, 2014 /PRNewswire/ -- VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of quantitative imaging solutions, today announced it will report its first quarter 2014 financial results before the market opens on Thursday, May 15, 2014.  Eric Converse, interim chief executive officer, and Jim Groff, acting chief financial officer, will host a conference call to discuss the company's financial results and provide a business update at 8:30 a.m. ET that morning.  Conference call and replay information is as follows:   

Domestic Call Dial In:  877-407-8035 International Call Dial In:  201-689-8035Conference Call ID:  13581706

An accompanying slide presentation to enhance managements' formal remarks, as well as a webcast of the call, can be accessed at http://www.virtualscopics.com/webcasts.aspx.

A replay and slide presentation will be available one hour after the conclusion of the conference call for 90 days, and can be accessed accordingly:

Replay Domestic Dial In:  877-660-6853Replay International Dial In:  201-612-7415Replay Conference Call ID:  13581706Webcast and slide presentation: http://www.virtualscopics.com/webcasts.aspx.

About VirtualScopics, Inc.VirtualScopics, Inc. (NASDAQ:VSCP) is a leading provider of quantitative imaging solutions to accelerate drug and medical device development.  For risk-adverse, time-constrained Clinical Trial Study Teams, Medical Directors and Imaging Scientists who require quality imaging data delivered on-time, within budget and on a consistent basis, VirtualScopics' clinical trial imaging solutions are an inspired true exception to commonly accepted services provided by other clinical trial imaging providers.  Because of the scientific and operational flexibility and responsiveness they can offer, VirtualScopics' clinical trial imaging solutions deliver special performance advantages compared to other image service providers that offer common, every day clinical trial imaging services.  For more information about VirtualScopics, Inc. please visit www.virtualscopics.com.

For more information, contact: Donna N. Stein, APR, Fellow PRSAManaging Partner, Donna Stein & Partners315-361-4672 dstein1@twcny.rr.com

SOURCE VirtualScopics, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,056.63 -23.51 -0.13%
S&P 500 2,114.15 -3.54 -0.17%
NASDAQ 5,067.22 -24.8650 -0.49%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs